TrialActa ophthalmologica2021

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study.

Xiaoxin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.